

Interim Result of Drug Repurposing Examination for COVID-19

April 30th, 2020 – Interprotein Corporation is pleased to announce that interim result of drug repurposing examination for COVID-19 has been obtained. This examination was executed to contribute to the termination of “COVID-19 Pandemic” and small molecule compounds that are predicted to bind to 3-chymotrypsin-like protease (3CLpro; also called Main protease and Mpro) were identified from approved drugs.

Above-mentioned small molecule compounds were predicted to show potent activities by AI-guided INTENDD®, a unique artificial intelligence (AI)-based activity prediction system for small molecule compounds, and eleven (11) compounds were identified so far. Although four (4) compounds of those have been already reported by other research laboratories, remaining seven (7) compounds have not been proposed by any laboratory, meaning that those are Interprotein-originated repurposing drug candidates. Interprotein has applied a medical use patent for those compounds and has a plan to prepare aiming at clinical studies in collaboration with other research organization.

Target compounds of our drug repurposing approach would be expanded to investigational drugs following approved drugs. Furthermore, Interprotein would initiate drug discovery research of new chemical entity (NCE) in preparation for the future coronavirus-caused pandemic.

Through the series of approaches, we contribute to decrease in the deaths due to the future new types of coronavirus as well as COVID-19 by our propriety technologies of molecular design and AI drug discovery.

Contact:

Hirotsugu KOMATSU, Ph. D., R&D and BD Division
Interprotein Corporation
E-mail : info@interprotein.com